Kavanagh, K., Pollock, K. G., Cuschieri, K., Palmer, T., Cameron, R. L., Watt, C., Bhatia, R., Moore, C., Cubie, H., Cruickshank, M., & Robertson, C. (2017). Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. The Lancet Infectious Diseases, 17(12), 1293-1302. https://doi.org/10.1016/S1473-3099(17)30468-1
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. /
Kavanagh, Kimberley; Pollock, Kevin G.; Cuschieri, Kate 等.
在:
The Lancet Infectious Diseases, 卷 17, 号码 12, 12.2017, 页码 1293-1302.
科研成果: 期刊稿件 › 文章 › 同行评审
Kavanagh, K, Pollock, KG, Cuschieri, K, Palmer, T, Cameron, RL, Watt, C, Bhatia, R, Moore, C, Cubie, H, Cruickshank, M & Robertson, C 2017, 'Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study', The Lancet Infectious Diseases, 卷 17, 号码 12, 页码 1293-1302. https://doi.org/10.1016/S1473-3099(17)30468-1
Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C 等. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. The Lancet Infectious Diseases. 2017 12月;17(12):1293-1302. doi: 10.1016/S1473-3099(17)30468-1
Kavanagh, Kimberley ; Pollock, Kevin G. ; Cuschieri, Kate 等. / Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland : a 7-year cross-sectional study. 在: The Lancet Infectious Diseases. 2017 ; 卷 17, 号码 12. 页码 1293-1302.
@article{ad04fafff7ad4ed1a541a983f13c3922,
title = "Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study",
author = "Kimberley Kavanagh and Pollock, {Kevin G.} and Kate Cuschieri and Tim Palmer and Cameron, {Ross L.} and Cameron Watt and Ramya Bhatia and Catherine Moore and Heather Cubie and Margaret Cruickshank and Chris Robertson",
note = "Funding Information: KGP received travel monies for attendance at the International Papillomavirus Conference 2015 from Sanofi. RB received speaker honoraria and travel expenses from Abbott Molecular. CM and KC report grants from Cepheid, Becton Dickinson, GeneFirst, EuroImmun, Self Screen, and non-financial support from Hologic. HC reports grants from GlaxoSmithKline and personal fees from Abbott Diagnostics. All other authors declare no competing interests. Funding Information: We acknowledge the previous work of Katy Sinka and Martin Donaghy in contributing to the protocol for this surveillance scheme. We thank the analysts at Information Services Division for their role in the linkage process and John Love at Health Protection Scotland for his data management advice. Monitoring and evaluation of the HPV immunisation programme in Scotland is funded by the Scottish Government. We acknowledge the funders, the Scottish Government and the Chief Scientists Office (grant number CZH/4/528). Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",
year = "2017",
month = dec,
doi = "10.1016/S1473-3099(17)30468-1",
language = "English",
volume = "17",
pages = "1293--1302",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "12",
}
TY - JOUR
T1 - Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland
T2 - a 7-year cross-sectional study
AU - Kavanagh, Kimberley
AU - Pollock, Kevin G.
AU - Cuschieri, Kate
AU - Palmer, Tim
AU - Cameron, Ross L.
AU - Watt, Cameron
AU - Bhatia, Ramya
AU - Moore, Catherine
AU - Cubie, Heather
AU - Cruickshank, Margaret
AU - Robertson, Chris
N1 - Funding Information:
KGP received travel monies for attendance at the International Papillomavirus Conference 2015 from Sanofi. RB received speaker honoraria and travel expenses from Abbott Molecular. CM and KC report grants from Cepheid, Becton Dickinson, GeneFirst, EuroImmun, Self Screen, and non-financial support from Hologic. HC reports grants from GlaxoSmithKline and personal fees from Abbott Diagnostics. All other authors declare no competing interests.
Funding Information:
We acknowledge the previous work of Katy Sinka and Martin Donaghy in contributing to the protocol for this surveillance scheme. We thank the analysts at Information Services Division for their role in the linkage process and John Love at Health Protection Scotland for his data management advice. Monitoring and evaluation of the HPV immunisation programme in Scotland is funded by the Scottish Government. We acknowledge the funders, the Scottish Government and the Chief Scientists Office (grant number CZH/4/528).
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/12
Y1 - 2017/12
UR - http://www.scopus.com/inward/record.url?scp=85030329926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030329926&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(17)30468-1
DO - 10.1016/S1473-3099(17)30468-1
M3 - Article
C2 - 28965955
AN - SCOPUS:85030329926
SN - 1473-3099
VL - 17
SP - 1293
EP - 1302
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 12
ER -
